Laddar...
Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines
Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...
Sparad:
| I publikationen: | Pharmaceutics |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
MDPI
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6723888/ https://ncbi.nlm.nih.gov/pubmed/31382388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11080384 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|